INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Erminia Massarelli, Ani Sarkis Balmanoukian, Maria Vieito, Christophe Le Tourneau, Tatiana Hernandez-Guerrero, Jose Manuel Trigo, Raid Aljumaily, Michael Jon Chisamore, Debra Rogan, Ruby Sung, Courtney Henry, David Turner, Sapna Yadavilli, Sonia Franco, Catherine Elizabeth Ellis, Marc S. Ballas, Axel Hoos, Danny Rischin
Institutions: City Of Hope National Medical Center, City of Hope, Cedars-Sinai Medical Center, Angeles Clinic and Research Institute, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Curie, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Ramón y Cajal, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Merck & Co., Inc., Rahway, NJ, USA (United States), GlaxoSmithKline (United States), The University of Melbourne, Peter MacCallum Cancer Centre
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3029332117